Equities research analysts expect DaVita Inc. (NYSE:DVA – Get Rating) to report $2.87 billion in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for DaVita’s earnings, with the lowest sales estimate coming in at $2.85 billion and the highest estimate coming in at $2.89 billion. DaVita posted sales of $2.82 billion during the same quarter last year, which suggests a positive year over year growth rate of 1.8%. The business is expected to report its next earnings report on Monday, January 1st.
On average, analysts expect that DaVita will report full-year sales of $11.87 billion for the current fiscal year, with estimates ranging from $11.74 billion to $11.92 billion. For the next year, analysts forecast that the firm will report sales of $12.26 billion, with estimates ranging from $12.10 billion to $12.40 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover DaVita.
DaVita (NYSE:DVA – Get Rating) last released its quarterly earnings data on Thursday, February 10th. The company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.22. The company had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.91 billion. DaVita had a net margin of 8.42% and a return on equity of 77.78%. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.67 EPS.
DaVita stock traded up $1.14 during trading hours on Friday, hitting $120.66. The company had a trading volume of 5,259 shares, compared to its average volume of 670,229. DaVita has a 1 year low of $94.38 and a 1 year high of $136.48. The company has a debt-to-equity ratio of 9.32, a quick ratio of 1.28 and a current ratio of 1.32. The firm has a market cap of $11.62 billion, a P/E ratio of 13.64, a P/E/G ratio of 1.47 and a beta of 1.18. The company has a 50-day moving average price of $114.23 and a two-hundred day moving average price of $110.58.
In related news, Director Paula A. Price sold 700 shares of the business’s stock in a transaction that occurred on Monday, February 14th. The shares were sold at an average price of $113.64, for a total transaction of $79,548.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.69% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. IFM Investors Pty Ltd increased its stake in DaVita by 6.2% during the 1st quarter. IFM Investors Pty Ltd now owns 11,165 shares of the company’s stock valued at $1,263,000 after purchasing an additional 655 shares in the last quarter. City Holding Co. increased its stake in DaVita by 33.6% during the 1st quarter. City Holding Co. now owns 1,570 shares of the company’s stock valued at $178,000 after purchasing an additional 395 shares in the last quarter. DNB Asset Management AS increased its stake in DaVita by 1.8% during the 1st quarter. DNB Asset Management AS now owns 13,213 shares of the company’s stock valued at $1,495,000 after purchasing an additional 237 shares in the last quarter. Wedmont Private Capital acquired a new position in DaVita during the 1st quarter valued at approximately $384,000. Finally, Humankind Investments LLC acquired a new position in DaVita during the 4th quarter valued at approximately $245,000. Institutional investors and hedge funds own 84.28% of the company’s stock.
DaVita Company Profile (Get Rating)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.